MRK Merck & Co.
NYSE · SEC CIK 310158 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $72.01M 21 sales by 11 insiders
- Filings on record
- 398 since 2021-07-02, latest 2026-08-13 17:02
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Zachary Jennifer | EVP, GC | — | $25.20M |
| DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | — | $11.29M |
| Guindo Chirfi | EVP, Access, Policy, Comms | — | $8.15M |
| Williams David Michael | EVP, Chief Info, Digital Off | — | $8.13M |
| Davis Robert M | COB, CEO, Pres, Dir | — | $5.60M |
| Litchfield Caroline | EVP, CFO | — | $5.02M |
| Li Dean Y | Pres, Executive VP, MRL | — | $2.99M |
| Maraldo David R. | EVP, Pres. MMD | — | $2.41M |
| Oosthuizen Johannes Jacobus | Pres, U.S. Market | — | $1.83M |
| Smart Dalton E. III | SVP Fin. - Gbl Ctrl | — | $766.0K |
Transactions 310
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-25 | 2023-01-23 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | A - Grant | $109.88 | +2,091 | 18.8K | +12% | +$229.8K | |
| 2023-01-25 | 2023-01-23 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | A - Grant | $109.88 | +2,846 | 43.9K | +7% | +$312.7K | |
| DM | 2023-01-11 | 2023-01-09 | MRK | Chattopadhyay Sanat | Exe V-P, Pres. MMD | S - Sale+OE | $112.29 | -84.0K | 69.4K | -55% | -$9.43M |
| D | 2023-01-11 | 2023-01-09 | MRK | Chattopadhyay Sanat | Exe V-P, Pres. MMD | M - OptEx | $53.06 | +84.0K | 113.5K | +285% | +$4.46M |
| DM | 2022-11-10 | 2022-11-08+ | MRK | MIZELL STEVEN | EVP, Chief HR Off | S - Sale+OE | $101.18 | -35.0K | 32.1K | -52% | -$3.54M |
| DM | 2022-11-10 | 2022-11-08+ | MRK | MIZELL STEVEN | EVP, Chief HR Off | M - OptEx | $0.00 | +35.0K | 52.1K | +204% | $0 |
| 2022-11-10 | 2022-11-09 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale | $103.21 | -1,795 | 16.7K | -10% | -$185.3K | |
| DM | 2022-11-10 | 2022-11-09 | MRK | Davis Robert M | CEO, Pres, Dir | S - Sale+OE | $102.44 | -167.6K | 327.6K | -34% | -$17.17M |
| D | 2022-11-10 | 2022-11-09 | MRK | Davis Robert M | CEO, Pres, Dir | M - OptEx | $0.00 | +167.6K | 415.2K | +68% | $0 |
| DM | 2022-11-08 | 2022-11-07 | MRK | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $99.55 | -235.8K | 785.4K | -23% | -$23.47M |
| D | 2022-11-08 | 2022-11-07 | MRK | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +235.8K | 936.4K | +34% | $0 |
| DM | 2022-11-07 | 2022-11-07 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $0.00 | +52.7K | 43.5K | New | $0 |
| D | 2022-11-07 | 2022-11-07 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale+OE | $99.47 | -45.6K | 18.5K | -71% | -$4.53M |
| DM | 2022-11-07 | 2022-11-03+ | MRK | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $98.66 | -470.0K | 721.0K | -39% | -$46.37M |
| DM | 2022-11-07 | 2022-11-03+ | MRK | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +470.0K | 935.7K | +101% | $0 |
| DM | 2022-11-03 | 2022-11-01+ | MRK | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $99.86 | -600.0K | 707.0K | -46% | -$59.92M |
| DM | 2022-11-03 | 2022-11-01+ | MRK | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +600.0K | 866.5K | +225% | $0 |
| DM | 2022-11-03 | 2022-11-01 | MRK | FRAZIER KENNETH C | Executive COB, Dir | G - Gift | $0.00 | -5,630 | 700.7K | -0.8% | $0 |
| DM | 2022-11-01 | 2022-10-28 | MRK | Chattopadhyay Sanat | Exe V-P, Pres. MMD | M - OptEx | $0.00 | +100.3K | 145.9K | +220% | $0 |
| D | 2022-11-01 | 2022-10-28 | MRK | Chattopadhyay Sanat | Exe V-P, Pres. MMD | S - Sale+OE | $100.10 | -100.3K | 45.6K | -69% | -$10.04M |
| DM | 2022-11-01 | 2022-10-28+ | MRK | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $100.44 | -867.1K | 935.6K | -48% | -$87.09M |
| DM | 2022-11-01 | 2022-10-28+ | MRK | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +867.1K | 1.27M | +213% | $0 |
| DM | 2022-11-01 | 2022-10-28 | MRK | MIZELL STEVEN | EVP, Chief HR Off | S - Sale+OE | $99.63 | -25.0K | 32.1K | -44% | -$2.49M |
| D | 2022-11-01 | 2022-10-28 | MRK | MIZELL STEVEN | EVP, Chief HR Off | M - OptEx | $0.00 | +17.0K | 57.1K | +42% | $0 |
| D | 2022-11-01 | 2022-10-28 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | S - Sale+OE | $100.21 | -3,633 | 10.9K | -25% | -$364.1K |
| D | 2022-11-01 | 2022-10-30 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | F - Tax | $100.77 | -450 | 11.3K | -4% | -$45.3K |
| D | 2022-11-01 | 2022-10-30 | MRK | Oosthuizen Johannes Jacobus | Pres, U.S. Market | M - OptEx | $100.77 | +913 | 11.8K | +8% | +$92.0K |
| D | 2022-11-01 | 2022-10-28 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | S - Sale+OE | $100.26 | -164.6K | 137.0K | -55% | -$16.50M |
| DM | 2022-11-01 | 2022-10-28 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | M - OptEx | $0.00 | +164.6K | 196.5K | +514% | $0 |
| D | 2022-11-01 | 2022-10-28 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | S - Sale+OE | $100.34 | -32.0K | 41.1K | -44% | -$3.21M |
| DM | 2022-11-01 | 2022-10-28 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $0.00 | +32.0K | 58.1K | +123% | $0 |
| DM | 2022-11-01 | 2022-10-28 | MRK | Zachary Jennifer | EVP, GC | M - OptEx | $0.00 | +148.6K | 123.0K | New | $0 |
| DM | 2022-11-01 | 2022-10-28 | MRK | Zachary Jennifer | EVP, GC | S - Sale+OE | $99.38 | -165.3K | 103.5K | -61% | -$16.42M |
| D | 2022-05-05 | 2022-05-04 | MRK | Garay Arpa | SVP Human Health Gbl Mktg | F - Tax | $87.10 | -259 | 2,109 | -11% | -$22.6K |
| D | 2022-05-05 | 2022-05-04 | MRK | Garay Arpa | SVP Human Health Gbl Mktg | M - OptEx | $87.10 | +907 | 2,368 | +62% | +$79.0K |
| D | 2022-05-05 | 2022-05-04 | MRK | LeCointe-Cephas Lisa | SVP Chief Ethics, Com Off | F - Tax | $87.10 | -279 | 3,664 | -7% | -$24.3K |
| D | 2022-05-05 | 2022-05-04 | MRK | LeCointe-Cephas Lisa | SVP Chief Ethics, Com Off | M - OptEx | $87.10 | +813 | 3,943 | +26% | +$70.8K |
| D | 2022-05-05 | 2022-05-04 | MRK | Oosthuizen Johannes Jacobus | SVP, U.S. Market | M - OptEx | $87.10 | +907 | 15.0K | +6% | +$79.0K |
| D | 2022-05-05 | 2022-05-04 | MRK | Oosthuizen Johannes Jacobus | SVP, U.S. Market | F - Tax | $87.10 | -447 | 14.5K | -3% | -$38.9K |
| D | 2022-05-05 | 2022-05-04 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | F - Tax | $87.10 | -436 | 15.3K | -3% | -$38.0K |
| D | 2022-05-05 | 2022-05-04 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | M - OptEx | $87.10 | +885 | 15.8K | +6% | +$77.1K |
| D | 2022-05-05 | 2022-05-04 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $87.10 | -326 | 41.1K | -0.8% | -$28.4K |
| D | 2022-05-05 | 2022-05-04 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $87.10 | +949 | 41.4K | +2% | +$82.7K |
| D | 2022-05-04 | 2022-05-03 | MRK | Li Dean Y | Pres, Executive VP, MRL | F - Tax | $87.65 | -381 | 16.5K | -2% | -$33.4K |
| D | 2022-05-04 | 2022-05-03 | MRK | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $87.65 | +773 | 16.8K | +5% | +$67.8K |
| D | 2022-05-04 | 2022-05-03 | MRK | LeCointe-Cephas Lisa | SVP Chief Ethics, Com Off | F - Tax | $87.65 | -155 | 3,130 | -5% | -$13.6K |
| D | 2022-05-04 | 2022-05-03 | MRK | LeCointe-Cephas Lisa | SVP Chief Ethics, Com Off | M - OptEx | $87.65 | +452 | 3,285 | +16% | +$39.6K |
| D | 2022-05-04 | 2022-05-03 | MRK | Oosthuizen Johannes Jacobus | SVP, U.S. Market | F - Tax | $87.65 | -381 | 14.1K | -3% | -$33.4K |
| D | 2022-05-04 | 2022-05-03 | MRK | Oosthuizen Johannes Jacobus | SVP, U.S. Market | M - OptEx | $87.65 | +773 | 14.4K | +6% | +$67.8K |
| D | 2022-05-04 | 2022-05-03 | MRK | Litchfield Caroline | EVP, CFO | M - OptEx | $87.65 | +773 | 27.8K | +3% | +$67.8K |
| D | 2022-05-04 | 2022-05-03 | MRK | Litchfield Caroline | EVP, CFO | F - Tax | $87.65 | -373 | 27.4K | -1% | -$32.7K |
| D | 2022-05-04 | 2022-05-03 | MRK | Garay Arpa | SVP Human Health Gbl Mktg | M - OptEx | $87.65 | +773 | 1,682 | +85% | +$67.8K |
| D | 2022-05-04 | 2022-05-03 | MRK | Garay Arpa | SVP Human Health Gbl Mktg | F - Tax | $87.65 | -221 | 1,461 | -13% | -$19.4K |
| D | 2022-05-04 | 2022-05-03 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | M - OptEx | $87.65 | +773 | 15.3K | +5% | +$67.8K |
| D | 2022-05-04 | 2022-05-03 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | F - Tax | $87.65 | -381 | 14.9K | -2% | -$33.4K |
| D | 2022-05-04 | 2022-05-03 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $87.65 | +902 | 40.8K | +2% | +$79.1K |
| D | 2022-05-04 | 2022-05-03 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $87.65 | -309 | 40.5K | -0.8% | -$27.1K |
| D | 2022-05-04 | 2022-05-03 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | F - Tax | $87.65 | -147 | 9,263 | -2% | -$12.9K |
| D | 2022-05-04 | 2022-05-03 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | M - OptEx | $87.65 | +427 | 9,410 | +5% | +$37.4K |
| D | 2022-05-03 | 2022-05-01 | MRK | Litchfield Caroline | EVP, CFO | F - Tax | $88.69 | -427 | 27.0K | -2% | -$37.9K |
| D | 2022-05-03 | 2022-05-01 | MRK | Litchfield Caroline | EVP, CFO | M - OptEx | $88.69 | +866 | 27.5K | +3% | +$76.8K |
| D | 2022-05-03 | 2022-05-01 | MRK | LeCointe-Cephas Lisa | SVP Chief Ethics, Com Off | F - Tax | $88.69 | -220 | 2,833 | -7% | -$19.5K |
| D | 2022-05-03 | 2022-05-01 | MRK | LeCointe-Cephas Lisa | SVP Chief Ethics, Com Off | M - OptEx | $88.69 | +640 | 3,053 | +27% | +$56.8K |
| D | 2022-05-03 | 2022-05-01 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | F - Tax | $88.69 | -427 | 14.5K | -3% | -$37.9K |
| D | 2022-05-03 | 2022-05-01 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | M - OptEx | $88.69 | +866 | 14.9K | +6% | +$76.8K |
| D | 2022-05-03 | 2022-05-01 | MRK | Li Dean Y | Pres, Executive VP, MRL | F - Tax | $88.69 | -523 | 16.1K | -3% | -$46.4K |
| D | 2022-05-03 | 2022-05-01 | MRK | Li Dean Y | Pres, Executive VP, MRL | M - OptEx | $88.69 | +1,061 | 16.6K | +7% | +$94.1K |
| D | 2022-05-03 | 2022-05-01 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $88.69 | -318 | 39.9K | -0.8% | -$28.2K |
| D | 2022-05-03 | 2022-05-01 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $88.69 | +928 | 40.2K | +2% | +$82.3K |
| D | 2022-05-03 | 2022-05-01 | MRK | Garay Arpa | SVP Human Health Gbl Mktg | M - OptEx | $88.69 | +866 | 1,156 | +299% | +$76.8K |
| D | 2022-05-03 | 2022-05-01 | MRK | Garay Arpa | SVP Human Health Gbl Mktg | F - Tax | $88.69 | -247 | 909 | -21% | -$21.9K |
| D | 2022-05-03 | 2022-05-01 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | M - OptEx | $88.69 | +577 | 9,181 | +7% | +$51.2K |
| D | 2022-05-03 | 2022-05-01 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | F - Tax | $88.69 | -198 | 8,983 | -2% | -$17.6K |
| D | 2022-05-03 | 2022-05-01 | MRK | Oosthuizen Johannes Jacobus | SVP, U.S. Market | F - Tax | $88.69 | -427 | 13.7K | -3% | -$37.9K |
| D | 2022-05-03 | 2022-05-01 | MRK | Oosthuizen Johannes Jacobus | SVP, U.S. Market | M - OptEx | $88.69 | +866 | 14.1K | +7% | +$76.8K |
| 2022-02-28 | 2022-02-24 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | A - Grant | $73.51 | +1,660 | 8,604 | +24% | +$122.0K | |
| 2022-02-28 | 2022-02-24 | MRK | Davis Robert M | CEO, Pres, Dir | A - Grant | $73.51 | +29.9K | 247.6K | +14% | +$2.20M | |
| 2022-02-28 | 2022-02-24 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | A - Grant | $73.51 | +3,478 | 39.3K | +10% | +$255.7K | |
| 2022-02-28 | 2022-02-24 | MRK | Klobuchar Michael A | EVP - Chief Strategy Off | A - Grant | $73.51 | +2,994 | 14.1K | +27% | +$220.1K | |
| 2022-02-28 | 2022-02-24 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | A - Grant | $73.51 | +16.0K | 133.9K | +14% | +$1.17M | |
| 2022-02-28 | 2022-02-24 | MRK | Gerberding Julie L. | EVP, Chief Patient Off | A - Grant | $73.51 | +9,550 | 48.7K | +24% | +$702.0K | |
| 2022-02-28 | 2022-02-24 | MRK | FRAZIER KENNETH C | Executive COB, Dir | A - Grant | $73.51 | +119.5K | 706.3K | +20% | +$8.78M | |
| 2022-02-28 | 2022-02-24 | MRK | Zachary Jennifer | EVP, GC | A - Grant | $73.51 | +18.4K | 53.4K | +53% | +$1.35M | |
| 2022-02-28 | 2022-02-24 | MRK | Litchfield Caroline | EVP, CFO | A - Grant | $73.51 | +2,429 | 26.6K | +10% | +$178.6K | |
| 2022-02-28 | 2022-02-24 | MRK | Li Dean Y | Pres, Executive VP, MRL | A - Grant | $73.51 | +3,023 | 15.5K | +24% | +$222.2K | |
| 2022-02-28 | 2022-02-24 | MRK | Chattopadhyay Sanat | Exe V-P, Pres. MMD | A - Grant | $73.51 | +19.8K | 113.0K | +21% | +$1.46M | |
| 2022-02-28 | 2022-02-24 | MRK | MIZELL STEVEN | EVP, Chief HR Off | A - Grant | $73.51 | +14.6K | 40.1K | +57% | +$1.07M | |
| D | 2022-02-14 | 2022-02-10 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | F - Tax | $76.53 | -477 | 6,944 | -6% | -$36.5K |
| D | 2022-02-14 | 2022-02-10 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | M - OptEx | $76.53 | +1,202 | 7,421 | +19% | +$92.0K |
| D | 2022-02-11 | 2021-02-10 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | M - OptEx | $75.04 | +1,167 | 3,660 | +47% | +$87.6K |
| D | 2022-02-11 | 2021-02-10 | MRK | Williams David Michael | EVP, Chief Info, Digital Off | F - Tax | $75.04 | -467 | 3,193 | -13% | -$35.0K |
| D | 2021-11-10 | 2021-11-09 | MRK | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +663.9K | 1.25M | +113% | $0 |
| DM | 2021-11-10 | 2021-11-09 | MRK | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $82.27 | -663.9K | 586.8K | -53% | -$54.61M |
| D | 2021-11-05 | 2021-11-04 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | M - OptEx | $0.00 | +29.8K | 146.7K | +25% | $0 |
| D | 2021-11-05 | 2021-11-04 | MRK | DeLuca Richard R. | EVP, Pres, Merck Animal Heallth | S - Sale+OE | $90.40 | -29.8K | 116.9K | -20% | -$2.69M |
| D | 2021-11-05 | 2021-11-04 | MRK | Litchfield Caroline | EVP, CFO | M - OptEx | $0.00 | +22.7K | 42.4K | +115% | $0 |
| D | 2021-11-05 | 2021-11-04 | MRK | Litchfield Caroline | EVP, CFO | S - Sale+OE | $91.00 | -18.3K | 24.1K | -43% | -$1.67M |
| D | 2021-11-04 | 2021-11-03 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | S - Sale+OE | $88.45 | -25.0K | 35.8K | -41% | -$2.21M |
| D | 2021-11-04 | 2021-11-03 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $0.00 | +25.0K | 60.8K | +70% | $0 |
| DM | 2021-11-03 | 2021-11-01 | MRK | Gerberding Julie L. | EVP, Chief Patient Off | M - OptEx | $0.00 | +96.3K | 135.4K | +246% | $0 |
Purchase Sale Sale after option exercise All abbreviations